TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27500908
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (CBT or IPT)
Study: 25440273
Drug: Methylprednisolone at
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone at anesthesia induction (30 mg/kg IV)
Study: 25440273
Drug: Methylprednisolone by
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone by CPB prime (30 mg/kg)
Study: 19304555
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release formulation of tramadol hydrochloride (TRH) based on osmotic technology
Study: 19304555
Drug: Commercial TRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial TRH tablets (control)
Study: 19304555
Drug: Optimized formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized formulation (batch IVB)
Study: 11575344
Drug: Ropivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 7.5 mg ml(-1)
Study: 11575344
Drug: Bupivacaine 5
Normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 5 mg ml(-1)
Study: 3578927
Drug: Anti-H1 antihistamines
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-H1 antihistamines
Study: 3578927
Drug: Oral cromolyn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cromolyn
Study: 3578927
Drug: Association of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association of H1 and H2 anti-histamine drugs
Study: 31982288
Drug: Zonisamide 50
Normalized name: zonisamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide 50 mg/day
Study: 29617585
Drug: Talc slurry
Normalized name: Talc
DrugBank: Talc (DB09511)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Talc slurry (4 g) administered through indwelling pleural catheter
Study: 29617585
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered through indwelling pleural catheter
Study: 26891133
Drug: Caffeine 500
Normalized name: aspirin-caffeine 500 mg-32 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 500 (400 mg caffeine with 500 mL water)
Study: 26891133
Drug: Water 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water 1500 (1500 mL water)
Study: 26891133
Drug: Water 500
Normalized name: Water 500 mL in 500 mL PARENTERAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water 500 (500 mL water)
Study: 1563810
Drug: Pefloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin (400 mg b.i.d.)
Study: 1563810
Drug: Cefotaxime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (1 g t.i.d.)
Study: 29858625
Drug: Soluble green/roasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble green/roasted coffee (6 g/day for 8 weeks)
Study: 28807576
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 10 mL kg−1 (G10)
Study: 28807576
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 12 mL kg−1 (G12)
Study: 28807576
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 15 mL kg−1 (G15)
Study: 26044075
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D supplementation (1000 mg calcium carbonate with 400 IU vitamin D daily)
Study: 20974015
Drug: Probiotic formulation
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic formulation (PF) consisting of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 administered for 30 days in humans
Study: 16203271
Drug: Capecitabine/docetaxel combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine/docetaxel combination therapy
Study: 2949057
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sertraline
Study: 2949057
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg sertraline
Study: 2949057
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg sertraline
Study: 506742
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg zimelidine
Study: 30037660
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of 25% albumin BID for three days
Study: 27067532
Drug: Conventional calcineurin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional calcineurin inhibitor (CNI) therapy
Study: 25060610
Drug: PRN injections
Normalized name: Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRN injections of 0.5 mg ranibizumab
Study: 25060610
Drug: Monthly injections
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly injections of 0.5 mg ranibizumab
Study: 25060610
Drug: Non-randomized subjects
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-randomized subjects receiving monthly injections
Study: 16504579
Drug: Eplerenone 25
Normalized name: eplerenone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 25 mg/day titrated to 50 mg/day
Study: 10024335
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Enalapril + Simvastatin)
Study: 7571926
Drug: Cerebrolysin injected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin injected in retrobulbar space and in combination with trental
Study: 29906741
Drug: My-GMC (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: My-GMC (Group medical consultations combined with tablet-based online app)
Study: 27390976
Drug: Bivalirudin IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin IV bolus of 0.75 mg/kg followed by an infusion of 1.75 mg/kg/h until the end of the PCI.
Study: 27390976
Drug: Heparin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (70 UI/kg) intravenous bolus.
Study: 17583798
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin 7.5 mg daily
Study: 7733478
Drug: Depogen with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depogen with heparin
Study: 30075741
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment according to NICE guidelines
Study: 24193233
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution at 5 mL/kg/h
Study: 24193233
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution at 5 mL/kg/h and dopamine 3 mg/kg/min
Study: 24193233
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution at 10 mL/kg/h
Study: 20233037
Drug: Low-fat, high-complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat, high-complex carbohydrate with 1.24 g high oleic sunflower oil supplement (LFHCC)
Study: 20233037
Drug: Low-fat, high-complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat, high-complex carbohydrate with 1.24 g long chain n-3 poly-unsaturated fatty acid (LC n-3 PUFA) supplement (LFHCCn-3)
Study: 12410780
Drug: Clonidine and
Normalized name: clonidine and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine and other symptomatic medications (up to 8 days)
Study: 7273012
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of 3‐4 mg/m2 iv every 10‐14 days
Study: 7273012
Drug: Continuous 5‐day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 5‐day infusion of 1‐1.2 mg/m2/day every 21 days
Study: 7273012
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion after failing to respond to bolus vindesine
Study: 25022119
Drug: Saturated moxa
Normalized name: Moxatag
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saturated moxa dosage group
Study: 25022119
Drug: Regular moxa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular moxa dosage group
Study: 19440837
Drug: Think Smart
Normalized name: benzalkonium chloride Topical Foam [Smart San]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Think Smart curriculum (school-based drug prevention curriculum)
Study: 17303783
Drug: Allopurinol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (600 mg oral dose) before lower arm occlusion
Study: 17303783
Drug: Allopurinol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (600 mg oral dose) before upper arm occlusion
Study: 15134107
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% xylocaine jelly and 0.5 ml of intracameral 1% lidocaine
Study: 15134107
Drug: Sub-Tenon infiltration
Normalized name: tenonitrozole
DrugBank: Tenonitrozole (DB13659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-Tenon infiltration with 2 ml of 2% xylocaine
Study: 2190630
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg controlled release (CR) salbutamol tablets twice daily
Study: 2190630
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg standard salbutamol tablets four times daily
Study: 677866
Drug: Ticarcillin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticarcillin plus gentamicin (T+G)
Study: 677866
Drug: Cephalothin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalothin plus gentamicin (C+G)
Study: 25618318
Drug: Sustained-release (SR)
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release (SR) 75-mg tramadol/650-mg acetaminophen after a single dose
Study: 25618318
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release (IR) 37.5-mg tramadol/325-mg acetaminophen after 2 doses
Study: 25618318
Drug: Sustained-release (SR)
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release (SR) formulation with food
Study: 25618318
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release (IR) formulation with food
Study: 15169807
Drug: Bevacizumab 15
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg plus carboplatin and paclitaxel
Study: 9766493
Drug: 9-cis retinoic
Normalized name: 9-cis-retinoic acid
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9-cis retinoic acid (RA) at doses ranging from 30 to 230 mg/m2/day
Study: 2984100
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg sublingually
Study: 2805362
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg per os bid for 3 months
Study: 1111464
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of prednisone and fluoxymesterone
Study: 31911341
Drug: Therapy stratified
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy stratified by endotype (intervention group)
Study: 25981528
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment with customized information and education
Study: 23864139
Drug: Radon spa
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radon spa therapy
Study: 23864139
Drug: Radon spa
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radon spa therapy in OA patients
Study: 16554580
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with an investigational drug
Study: 11375828
Drug: IV injection
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection of 2 g propacetamol every 6 h for 3 days after surgery
Study: 9404448
Drug: rhGH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH therapy (0.25 IU/kg/week sc)
Study: 12061306
Drug: Chlorhexidine solution
Normalized name: CHLORHEXIDINE GLUCONATE 99.0 g in 1 L TOPICAL SOLUTION [CHLORHEXIDINE Solution]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine solution (1.2%)
Study: 2907896
Drug: GnRH (gonadotropin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH (gonadotropin releasing hormone)
Study: 18294761
Drug: Electrostimulated acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrostimulated acupuncture (EA) weekly for 12 weeks
Study: 18294761
Drug: Traditional acupuncture
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional acupuncture (TA) weekly for 12 weeks
Study: 3983422
Drug: Misonidazole (1
Normalized name: Fluoromisonidazole (18-F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misonidazole (1 g/m2, total 13-14 g/m2) given on every irradiation day
Study: 3983422
Drug: Radiotherapy (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy (3 daily fractions of 1.6 Gy for 2 weeks, total dose 48 Gy, boost to about 70 Gy after 3-4 weeks)
Study: 31265730
Drug: Azathioprine (IFX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (IFX 0 mg/kg)
Study: 29754251
Drug: Medication reconciliation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reconciliation and counselling intervention delivered by a pharmacist
Study: 26393904
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (tamsulosin 0.4 mg and tolterodine 4 mg)
Study: 26393904
Drug: Monotherapy (tamsulosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (tamsulosin 0.4 mg and placebo)
Study: 22315282
Drug: Low-dose BH4
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose BH4 (400 mg/d)
Study: 22315282
Drug: High-dose BH4
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose BH4 (700 mg/d)
Study: 27310958
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl 25 μg
Study: 19897803
Drug: Systemic hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic hydromorphone 1 mg IV and 1 mg IM
Study: 18569914
Drug: Oral 300,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 300,000 IU cholecalciferol supplementation
Study: 10695779
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg single dose of oral dihydroartemisinin (DHA)
Study: 8961361
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 325 mg daily for 1 year
Study: 1901203
Drug: Lithium-imipramine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium-imipramine combination
Study: 6349943
Drug: Hydrocortisone valerate
Normalized name: Hydrocortisone Valerate
DrugBank: Hydrocortisone valerate (DB14544)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone valerate 0.2 percent ointment
Study: 16876559
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (medical therapy only)
Study: 31115908
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg every 2 weeks (Q2W)
Study: 30215677
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg Q2W
Study: 31115908
Drug: Nivolumab 10
Normalized name: nivolumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 10 mg/kg Q2W (global population)
Study: 25091664
Drug: BRV-TV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRV-TV vaccine (10^5.0 FFU)
Study: 25091664
Drug: BRV-TV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRV-TV vaccine (10^5.8 FFU)
Study: 25091664
Drug: BRV-TV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRV-TV vaccine (10^6.4 FFU)
Study: 19717345
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (n=251)
Study: 11917277
Drug: Amifostine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (500 mg) administered before each chemotherapy cycle in the phase II trial and before carboplatin administration in the intensification trial.
Study: 11917277
Drug: Conventional radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy (60 Gy) and carboplatin (700 mg/m² cumulative dose) without amifostine in the control group of the phase II trial.
Study: 11917277
Drug: Carboplatin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (70 mg/m²) on specific days during radiotherapy in the intensification trial.
Study: 9814616
Drug: DCLHb 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCLHb 25 mg/kg
Study: 9814616
Drug: DCLHb 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCLHb 50 mg/kg
Study: 9814616
Drug: DCLHb 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCLHb 100 mg/kg
Study: 7503066
Drug: DCLHb (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCLHb (all doses)
Study: 22448480
Drug: 2-glass test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-glass test before finger rectal test (FRT)
Study: 9330936
Drug: Iloprost infusion
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost infusion (2 ng/kg/min for 8 hours)
Study: 9330936
Drug: Iloprost (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost (9 infusions over 6 months)
Study: 9330936
Drug: Nifedipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (40 mg/day for 6 months)
Study: 3519382
Drug: Defibrotide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide (200 mg IV four times a day for 7 days)
Study: 30289950
Drug: Darapladib (Lp‐PLA2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darapladib (Lp‐PLA2 inhibitor)
Study: 15712536
Drug: Serial lumbar
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial lumbar puncture and acetazolamide combination
Study: 12540416
Drug: Probiotic fermented
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic fermented milk drink (65 mL with Lactobacillus GG, Bifidobacterium sp B420, Lactobacillus acidophilus 145, and Streptococcus thermophilus; n = 108)
Study: 12540416
Drug: Standard yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard yogurt (180 g; n = 101)
Study: 8858355
Drug: BSS Plus
Normalized name: BSS Plus
DrugBank: Sodium phosphate, dibasic, unspecified form (DB14504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSS Plus with heparin and dexamethasone (HD)
Study: 1516609
Drug: Oral alprazolam
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alprazolam (1 mg)
Study: 1516609
Drug: Sublingual alprazolam
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual alprazolam (1 mg)
Study: 9386146
Drug: Placebo (sublingual)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sublingual)
Study: 1516609
Drug: Both routes
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both routes of alprazolam (oral and sublingual)
Study: 20047095
Drug: low-dose cytosine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose cytosine arabinoside and aclarubicin (CA)
Study: 12454227
Drug: Diclofenac infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac infusion
Study: 31665842
Drug: Five-in-one asthma
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-in-one asthma management model (standardized asthma treatment, asthma diary, PEF monitoring, reasonable diet and physical exercise)
Study: 31665842
Drug: Routine medication
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medication and regular outpatient consultation (control group)
Study: 25420010
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and exercise program aimed at increasing the size of the intervertebral foramen (IVF) of the affected nerve root
Study: 25420010
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and exercise program without the specific goal of increasing the size of the IVF
Study: 25420010
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and exercise program aimed at increasing the size of the IVF of the affected nerve root
Study: 21505984
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (conventional therapy plus continuous insulin pumping to control blood glucose at 4.4‐6.1 mmol/L)
Study: 17584491
Drug: HIV RNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV RNA levels <400 copies/ml at delivery
Study: 11471097
Drug: Ribavirin monotherapy
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin monotherapy for an additional 6 months
Study: 8241852
Drug: Placebo soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo soft laser treatment
Study: 31205105
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) 35 mg orally twice a day for 3 months